{"id":"W4399302782","doi":"10.1097/hc9.0000000000000430","title":"Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future","year":2024,"lang":"en","type":"review","venue":"Hepatology Communications","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Genentech; Sirtex Medical; Ipsen; Eisai; Wellcome Trust; National Institute on Minority Health and Health Disparities; Stryker; Exelixis; Bayer HealthCare; Incyte; Boston Scientific Corporation; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Contraindication; Oncology; Systemic therapy; Adjuvant; Adjuvant therapy; Clinical trial; Internal medicine; Intensive care medicine; Neoadjuvant therapy; Cancer; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004172345,0.0004101702,0.001944874,0.0002942756,0.000169151,0.00004364621,0.0003347103,0.0003304863,0.00001158228],"category_scores_gemma":[0.00002977637,0.0002217391,0.0002792186,0.0003745356,0.0005838897,0.00003233454,0.0004093884,0.001173958,0.00004507522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001217955,"about_ca_system_score_gemma":0.0004166013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001131891,"about_ca_topic_score_gemma":0.0002257837,"domain_scores_codex":[0.9975034,0.001024257,0.0006688338,0.0003841359,0.0001091922,0.0003101768],"domain_scores_gemma":[0.9974188,0.0005766522,0.0001843475,0.001644908,0.00005009445,0.0001251565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002529127,0.00009349886,0.0237795,0.004145073,0.0003043227,0.00003618357,0.0007730956,1.053881e-9,4.906598e-8,0.004784532,0.0003449784,0.9657135],"study_design_scores_gemma":[0.001401096,0.00007285901,0.0001802398,0.00721233,0.002201764,0.0009268519,0.000129825,0.0002166116,5.480495e-8,0.0002106032,0.9872604,0.0001873726],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001271964,0.992606,0.000001154729,0.003056608,0.0002558384,0.002459442,0.00004648169,0.0000605883,0.0002419241],"genre_scores_gemma":[0.02210345,0.9758465,0.00008939194,0.00009284624,0.00008206927,0.00125381,0.0004253458,0.00004998053,0.00005660247],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9869154,"threshold_uncertainty_score":0.9042256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1379420957450176,"score_gpt":0.3704256802017087,"score_spread":0.2324835844566912,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}